Phase II Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This Phase II trial is to see how well single agent chemotherapy and pembrolizumab work
elderly patients (≥ 75 years) with advanced non small cell lung cancer (NSCLC). Pembrolizumab
stimulates your immune system to help fight lung cancer. This treatment approach may be
better tolerated in elderly patients.